Business
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission Topline Safety, Tolerability and Immunogenicity Data from OPUS-1 Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Results Expected in First Half of 2027 Enrollment Completed in VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series and Boos
About this update from Vaxcyte, Inc.
[{"type":"image","alt":"Vaxcyte, Inc.","displaySize":"","headline":null,"caption":"Vaxcyte, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":116,"url":"https://media.zenfs.com/en/globenewswire.com/4603e333819538d7d741e3ecc95e1d72"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UD9p7QfAhQocG_mwSinWcQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4603e333819538d7d741e3ecc95e1d72","width":300,"height":116}},"lazy":false},{"type":"text","content":"Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission","length":181,"tagName":"p"},{"type":"text","content":"Topline Safety, Tolerability and Immunogenicity Data from OPUS-1 Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Results Expected in First Half of 2027","length":157,"tagName":"p"},{"type":"text","content":"Enrollment Completed in VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series and Booster Dose Expected Either Sequentially or Together by End of First Half of 2027","length":238,"tagName":"p"},{"type":"text","content":"Company Advancing Early-Stage Pipeline, Expects to Initiate Phase 1 Adult Clinical Study for VAX-A1, a Vaccine Candidate to Prevent Group A Strep, in 2026","length":154,"tagName":"p"},{"type":"text","content":"Company Advances Global and U.S. Manufacturing Capabilities to Support Commercialization of Pneumococcal Conjugate Vaccines with Completion of Dedicated Lonza Facility and Initiation of North Carolina Fill-Finish Line Buildout","length":226,"tagName":"p"},{"type":"text","content":"Approximately $2.4 Billion in Cash, Cash Equivalents and Investments as of December 31, 2025; Excludes Approximately $600.2 Million in Net Proceeds from February 2026 Equity Offering","length":187,"tagName":"p"},{"type":"text","content":"Company to Host Webcast/Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT","length":76,"tagName":"p"},{"type":"text","content":"SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a bu...